Recombinant human activated protein C in the treatment of severe sepsis: An evidence-based review

Critical Care Medicine

Volumn 32, Issue 11 SUPPL., 2004, Pages

  Fourrier, François ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; HEPARIN; RECOMBINANT PROTEIN; WARFARIN;

BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEATH; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEALTH CARE ORGANIZATION; HUMAN; INTENSIVE CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; RISK ASSESSMENT; SEPSIS;

EID: 8444244831     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000145944.64532.53     Document Type: Review

References (44)

1. Esmon CT: The protein C pathway. Crit Care Med 2000; 28(Suppl):S44-S48
2. Taylor FB Jr, Peer GT, Lockhart MS, et al: Endothelial cell protein C receptor plays an important role in protein C activation in vivo. Blood 2001; 97:1685-1688
3. Faust SN, Heyderman RS, Levin M: Coagulation in severe sepsis: A central role for thrombomodulin and activated protein C. Crit Care Med 2001; 29(Suppl):S62-S68
4. Oliver JA, Monroe DM, Church FC, et al: Activated protein C cleaves factor Va more efficiently on endothelium than on platelet surfaces. Blood 2002; 100:539-546
5. Joyce DE, Grinnell BW: Recombinant activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κB. Crit Care Med 2002; 30:S288-S293
6. Fourrier F, Chopin C, Goudemand J, et al: Septic shock, multiple organ failure and disseminated intravascular coagulation: compared patterns of antithrombin III, protein C and protein S deficiencies. Chest 1992; 101:816-823
7. Fijnvandraat K, Derkx B, Peters M, et al: Coagulation activation and tissue necrosis in meningococcal septic shock: Severely reduced protein C levels predict high mortality. Thromb Haemost 1995; 75:15-20
8. Yan BS, Helterbrand JD, Hartman DL, et al; Low levels of protein C are associated with poor outcome in severe sepsis. Chest 2001; 120:915-922
9. Faust SN, Levin M, Harrison OB, et al: Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001; 345:408-416
10. Van BS, Dhainaut JF: Activated protein C versus protein C in severe sepsis. Crit Care Med 2001; 29(Suppl):S69-S74
11. Hazelzet JA, De Kleijn ED, De Groot R: Endothelial protein C activation in meningococcal sepsis. N Engl J Med 2001; 345:1776-1777
12. de Kleijn E, de Groot R, Hack CE, et al: Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized double-blinded placebo controlled dose finding study. Crit Care Med 2003; 31:1839-1847
13. Taylor FB, Chang A, Esmon CT, et al: Protein C prevents the coagulopathic effects of E. coli infusion in the baboon. J Clin Invest 1987; 79:918-925
14. Fourrier F, Jourdain M, Tournoys A, et al: Effect of a combined antithrombin III and PC substitution in experimental porcine acute endotoxin shock. Shock 1998; 10:364-370
15. Taylor FB, Dahlback B, Chang AC, et al: Role of the free protein S and C4b binding protein in regulating the coagulant response to Escherichia coli. Blood 1995; 86:2642-2652
16. Gerson WT, Dickerman JD, Bovill EG, et al: Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate. Pediatrics 1993; 91:418-421
17. Rivard GE, David M, Farrell C, et al: Treatment of purpura fulminans in meningococcemia with protein C concentrates. J Pediatr 1995; 126:646-652
18. Smith OP, White B, Vaughan D, et al: Use of protein C concentrate, heparin and haemodiafiltration in meningococcus-induced purpura fulminans. Lancet 1997; 350: 1590-1593
19. Ettingshausen C, Veldmann A, Beeg T, et al: Replacement therapy with protein C concentrate in infants and adolescents with meningococcal sepsis and purpura fulminans. Semin Thromb Hemost 1999; 25:537-541
20. Betrosian AP, Balla M, Kofinas G, et al: Protein C in the treatment of coagulopathy in meningococcal sepsis. Crit Care Med 1999; 27:2849-2850
21. Rintala E, Kauppila M, Seppala OP, et al: Protein C substitution in sepsis-associated purpura fulminans. Crit Care Med 2000; 28: 2373-2378
22. White B, Livingstone W, Murphy C, et al: An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia. Blood 2000; 96:3719-3724
23. Fourrier F, Leclerc F, Aidan K, et al: Combined antithrombin and PC supplementation in meningococcal purpura fulminans: A pharmacokinetic study. Intensive Care Med 2003; 29:1081-1087
24. Macias WL, Dhainaut JF, Van BS, et al: Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther 2002; 72:391-402
25. Bernard GR, Ely EW, Wright TJ, et al: Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001; 29:2051-2059
26. Bernard GR, Vincent JL, Laterre PF, et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709
27. Angus DC, Laterre PF, Elterbrand J, et al: The effects of drotrecogin alfa (activated) on long term survival after severe sepsis. Abstr. Chest 2002; 122:51S
28. Laterre PF, Levy H, Balk D, et al: The effects of drotrecogin alfa (activated) on hospital mortality, length of stay and discharge location. Abstr. Chest 2002; 122:515
29. Manns BJ, Lee H, Doig CJ, et al: An economic evaluation of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347: 993-999
30. Warren HS, Suffredini AF, Eichacker PQ, et al: Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002; 347:1027-1030
31. Angus DC, Linde-Zwirbie WT, Clermont G, et al: Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med 2003; 31:1-11
32. Schein RMH, Kinasewitz GT: Risk-benefit analysis for drotrecogin alfa (activated). Am J Surg 2002; 184:25-38S
33. Ely EW, Laterre PF, Angus DC, et al: Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31:12-19
34. Vincent JL, Angus DC, Aetigas A, et al: Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31:834-840
35. Dhainaut JF, Laterre PF, Janes JM, et al: Drotrecogin alfa (activated) in the treatment of severe sepsis patients with multiple organ dysfunction: data from the PROWESS trial. Intensive Care Med 2003; 29:894-903
36. Kerlin BA, Yan SC, Isermann BH, et al: Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia. Blood 2003; 102:3085-3092
37. Laterre PF, Heiselman D: Management of patients with severe sepsis treated by drotrecogin alfa (activated). Am J Surg 2002; 184:398-468
38. Bernard GR, Macias WL, Joyce DE, et al: Safety assessment of drotrecogin alfa (acti-vated) in the treatment of adult patients with severe sepsis. Crit Care 2003; 7:155-163
39. Rezaie AR: Exosite-dependent regulation of the protein C anticoagulant pathway. Trends Cardiovasc Med 2003; 13:8-15
40. Stearns-Kurosawa DJ, Swindle K, D'Angelo A, et al: Plasma levels of endothelial protein C receptor respond to anticoagulant treatment. Blood 2002; 99:526-530
41. Linder R, Frebelius S, Jansson K, et al: Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors. Blood Coagul Fibrinolysis 2003; 14:139-146
42. Berg DT, Gerlitz B, Shang J, et al: Engineering the proteolytic specificity of activated protein C improves its pharmacological properties. Proc Natl Acad Sci U S A 2003; 100:4423-4428
43. Derhaschnig U, Reiter R, Baumgartner M, et al: Recombinant human activated protein C (rhAPC, drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia. Blood 2003; 102:2093-2098
44. Kalil AC, Coyle SM, Um JY, et al: Effects of drotrecogin alfa (activated) in human endotoxemia. Shock 2004; 21:222-229